Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | DDX3X | O00571 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579476 | 1.00 | SPR (0.48) | SPRDDX3XLMNAKDM4EKMT2A | |
| SCHEMBL3572797 | 0.85 | SPR (0.46) | SPRKMT2AALDH1A1GFERNPC1 | |
| SCHEMBL594973 | 0.85 | SPR (0.46) | SPRKMT2AALDH1A1GFERNPC1 | |
| SCHEMBL594972 | 0.85 | SPR (0.46) | SPRKMT2AALDH1A1GFERNPC1 | |
| SCHEMBL6111608 | 0.85 | SPR (0.57) | SPRKDM4ETLR8TLR7NPC1 | |
| SCHEMBL5244703 | 0.85 | SPR (0.57) | SPRKDM4ETLR8TLR7NPC1 | |
| SCHEMBL23360316 | 0.85 | POLB (0.56) | SPRLMNAKDM4E | |
| SCHEMBL23360317 | 0.85 | POLB (0.56) | SPRLMNAKDM4E | |
| SCHEMBL21856356 | 0.82 | EPHX2 (0.57) | LMNAKMT2ARAB9A | |
| SCHEMBL21856361 | 0.82 | EPHX2 (0.57) | LMNAKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | SPR 3903/4885DDX3X 864/4885LMNA 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.